Home > Chemotherapeutics > Jbr
JOURNEY BEYOUND RESILLIENCE
Cabazitaxel
Class
Microtubule Inhibitor.
MOA
Jbr is a microtubule inhibitor. It binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.
Indications
Hormone-refractory metastatic prostate cancer
Side Effects
Most common all grades adverse reactions (≥10%) are:
- Neutropenia
- Diarrhea
- Constipation
- Back Pain
- Pyrexia
- Arthralgia
- Hematuria
- Anemia
- Fatigue
- Asthenia
- Anorexia
- Dyspnea
- Alopecia
- Cough
- Leukopenia
- Nausea
- Abdominal Pain
- Peripheral Neuropathy
- Dysgeusia
- Thrombocytopenia
- Vomiting
Dose
Jbr 25 mg/m2 is administered every three weeks as a one-hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Jbr treatment.
Pack Size
1’s
Storage
15°-30° C
Available Strength
60 mg/ 1.5 ml